AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01130428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvent 1000 Vibration Platform
Description: As a mechanical intervention, mechanical stimulation in the form of vibration will be administered to the forearm using a Juvent 1000 Vibration Platform (Juvent Medical, Inc., Lakeland, FL, USA), which is a non-medicinal product. The device produces gentle, low-magnitude mechanical signals in the form of low-amplitude vertical displacements at a high frequency.~The intervention in the present study will be given at a fixed dosage that is defined by the intensity of vibration: frequency: 90 Hz, amplitude: 10 µm (\~3.0 g). The mechanical stimulation will be administered in an intermittent fashion, as it has been shown that inserting short rest periods between loading cycles enhances the efficacy of mechanical loading \[38\]. Thus, the mechanical stimulation will be administered for three times 10 minutes (i.e. the vibration platform turned on), with 10-minute rest periods in between (i.e. the vibration platform turned off); the intervention will have a total duration of 50 minutes.
Study NCT04986254 — intervention group
Intervention type: DRUG
Intervention: Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam
Description: Antibiotic dose and dosing interval will be determined by the treating clinician in accordance to standard prescribing practices based on clinical assessment of the patient. This study aims to recruit at least 20 participants per antibiotic.
Study NCT02915601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Study NCT01929993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWETZ
Description: Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
Study NCT02915601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01929993 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ cone
Description: LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth. The loop is applied to the cervix outside the lateral margin of the transformation zone and brought slowly to the controlateral transformation zone margin.
Study NCT01632449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test product
Description: Dimethyl Fumarate (BG00012)
Study NCT01632449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference product
Description: Dimethyl Fumarate (BG00012)
Study NCT04274829 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroidecomt and lymphectomy
Description: Patients underwent total thyroidectomy or lobectomy associated to lymph node sampling or neck lymphectomy
Study NCT01680367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound care management
Description: Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing
Study NCT01680367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound care management
Description: Receive native collagen wound dressing
Study NCT01680367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03680261 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: CRT (1 cycle CT: Xelox or SOX, Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
Study NCT03680261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: CT (6 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
Study NCT04012216 — intervention group
Intervention type: DEVICE
Intervention: Measure of mandibular movement using a mid-sagittal magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium)
Description: A mid-sagittal MM magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium) measures the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and on the chin. Measurements last one night.
Study NCT04012216 — intervention group
Intervention type: DEVICE
Intervention: Gold standard: polysomnography
Description: Polysomnography will be performed according to the American Academy of Sleep Medicine Recommendations 2018
Study NCT04955015 — intervention group
Intervention type: PROCEDURE
Intervention: carotid endarterectomy
Description: patients with carotid atherosclerosis refering to CEA
Study NCT04580615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardiacSense1 and capnograph Respiratory rate measurement
Description: Inpatients Subjects with respiratory disease/impairment and Inpatients Subjects with no known respiratory disease/impairment will be measured simultaneously with both CardiacSense1 and capnograph for at least 30 minutes up to 24 hours. During this time capnograph data will be recorded in parallel to CardiacSense1.
Study NCT03121937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App
Description: The mobile app mConnect is an app designed to facilitate psychotherapy for depression and includes mood tracking, goal setting, and communication
Study NCT04155840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study NCT01335685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules
Study NCT01335685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan tablets
Study NCT01335685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets
Study NCT03912896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taekwondo
Description: Children will participate in a 7-week taekwondo program.
Study NCT02136108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPENtext
Description: Participants will receive 12 weeks of daily text messages sent from an automated system. The text messages will assist participants in managing their chronic pain.
Study NCT02136108 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPENnav
Description: Particpants will be linked with a RIPN PEER Navigator who will assisted them in managing their health care
Study NCT03012516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAP-treatment by physiotherapist
Study NCT03012516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary PAP-treatment at the health care center
Study NCT02469376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-GP1
Description: Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
Study NCT04378946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive physical rehabilitation type training
Description: Multiple reaching tasks aiming at increasing voluntary elbow range of motion
Study NCT04378946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive physical rehabilitation type training
Description: Multiple reaching tasks aiming at increasing voluntary elbow range of motion
Study NCT04378946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic system for supporting and monitoring arm motion
Description: Ergonomic double-joint horizontal manipulandum mounted on a rigid, movable arm (used to support UL movement during tasks).~An electromyogram (EMG) is used to monitor elbow extensor and flexor muscle activity.~A motion tracking device based on the Kinect II skeleton ( with Kalman filter to improve accuracy).~Simple Virtual Reality Reaching Game providing visual feedback with screen display of the subject's arm avatar and arm workspace for the VR training.
Study NCT04378946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic system for supporting and monitoring arm motion
Description: Ergonomic double-joint horizontal manipulandum mounted on a rigid, movable arm (used to support UL movement during tasks).~An electromyogram (EMG) is used to monitor elbow extensor and flexor muscle activity.~A motion tracking device based on the Kinect II skeleton ( with Kalman filter to improve accuracy).~Simple Virtual Reality Reaching Game providing visual feedback with screen display of the subject's arm avatar and arm workspace for the VR training.
Study NCT04378946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Actigraph Activity Monitor
Description: Used during and outside training sessions, this device is worned on the affected wrist that records activity (movements metrics) as a measure of upper extremity as well as heart rate
Study NCT04378946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph Activity Monitor
Description: Used during and outside training sessions, this device is worned on the affected wrist that records activity (movements metrics) as a measure of upper extremity as well as heart rate
Study NCT04378946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Description: Done once before treatment (PRE)
Study NCT04378946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: Done once before treatment (PRE)
Study NCT04378946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Montreal Spasticity Measure (MSM)
Description: Used to identify the actual spatial threshold (ST) prior to every training session
Study NCT04378946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Montreal Spasticity Measure (MSM)
Description: Used to identify the actual spatial threshold (ST) prior to every training session
Study NCT04473625 — intervention group
Intervention type: OTHER
Intervention: Stool Sample Collection
Description: Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Study NCT04155840 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04155840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV
Study NCT04913545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: using salivary miRNA (412,512)
Description: quantitative real time polymerase chain reaction to detect the salivary miRNAs 412,512) to indicate the malignant transformation in potientially malignant oral lesions.
Study NCT01234324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin, Cisplatin, Capecitabine, Panitumumab
Description: Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
Study NCT01234324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin, Cisplatin, Capecitabine
Description: Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
Study NCT01144845 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracic surgery
Description: Thoracoscopy or anterior thoracotomy
Study NCT03247686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RSLV-132
Description: RNase Fc fusion protein
Study NCT03247686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04252716 — intervention group
Intervention type: DEVICE
Intervention: OVD
Description: Intraocular administration
Study NCT02874196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard arthrography
Study NCT02874196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual energy arthrography
Study NCT02874196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthro-tomosynthesis
Study NCT04727775 — intervention group
Intervention type: DRUG
Intervention: Favipiravir
Description: Antiviral drugs
Study NCT02874196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthro-tomography
Study NCT02874196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery on painful prosthesis
Description: Possibly performed during 6 months from arthrography
Study NCT01096745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin
Description: D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks
Study NCT01096745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Cisplatin
Description: D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
Study NCT04506567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-J591
Description: Single cycle of fractionated dose of 225Ac-J591
Study NCT04506567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-HBED-CC injection
Description: 68Ga-PSMA-HBED-CC PET/CT before and after treatment
Study NCT04506567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-J591
Description: Single dose of 225Ac-J591 every 6 weeks x 4
Study NCT04204096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT (Multi-dose formulation)
Description: * Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (multi dose Vi-DT with preservative 2 PE)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2 to 45 years~* Storage Conditions: +2 to +8°C
Study NCT04204096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT (Single dose formulation)
Description: * Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (single dose Vi-DT without any preservative)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2-45 years~* Storage Conditions: +2 to +8°C
Study NCT04204096 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Vaccine
Description: * For participant ≥ 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered~* For participants 6 months to 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered during the study and the next dose will be provided after the study unblinding at the completion of 6 months follow up of last subject.
Study NCT01944553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ROSA™ robot
Description: The ROSA™ robot can assist in identifying the pedicle entry point and in controlling the screw trajectory through a system of continuous monitoring of patient motion. This process strengthens the accuracy of pedicle screws implantation.~Stabilisation in treatment for spine degenerative disease
Study NCT03568604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasterone
Description: 6.5 vaginal insert prasterone (dehydroepiandrosterone)
Study NCT02276625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: Compare ID administration to IM administration. 1 visit schedule.
Study NCT02276625 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rabies vaccine
Description: Compare ID administration to IM administration. 1 visit schedule.
Study NCT04453969 — intervention group
Intervention type: OTHER
Intervention: COVID-19
Description: Exposure of interest for this observational study is current COVID-19 positive status or COVID-19 positive status during pregnancy
Study NCT01173861 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity counseling
Description: 20-30 minutes of face-to-face physical activity counseling using motivational interviewing followed by 3 20 minute telephone counseling sessions.
Study NCT01173861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Description: 20-30 minutes of face-to-face physical activity counseling using motivational interviewing followed by 3 20 minute telephone counseling sessions.
Study NCT03861611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Participants may be randomized to receive Ketorolac oral medication 10 mg, every 8 hours for 5 days as needed
Study NCT02086617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound of aorta
Study NCT02369354 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TALKS Social Worker Intervention
Description: TALKS includes a video and book that describe patient and family experiences with talking about and considering live kidney transplantation. TALKS also includes a social worker meeting. Potential recipients meet with a transplant social worker for up to 60 minutes to identify potential barriers to considering or pursuing live donor kidney transplantation. They also are invited to have a second meeting with family and/or friends with the social worker for up to 60 minutes.
Study NCT03861611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Participants may be randomized to receive Ibuprofen oral medication 600 mg, every 8 hours for 5 days as needed
Study NCT03861611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Participants may be randomized to receive Diflofenac oral medication 50 mg, every 8 hours for 5 days as needed
Study NCT03861611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
Study NCT01981759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.
Study NCT01981759 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 12 weekly administrations of placebo by mouth 1 hour before CBT sessions, from weeks 1-12.
Study NCT01981759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
Study NCT01981759 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
Study NCT02369354 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Financial Assistance Intervention
Description: The financial assistance intervention offers potential donors the ability to draw from a bank of $2100 to reimburse their costs related to being evaluated for live kidney donation or for donating a kidney. Costs include, but are not limited to: child care, travel, time off work, and other out of pocket expenses related to being evaluated to become a live kidney donor or to donating.
Study NCT02199860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD I
Study NCT02199860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD II
Study NCT02199860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02199860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03269461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angiography and Optical Coherence Tomography evaluations
Description: coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations
Study NCT01836224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) >65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
Study NCT01836224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline
Description: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65
Study NCT00993161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motriplate
Description: Number of contact couples